Show news: from last 30 days (default), 60 days, 90 days, last visit or all

Risks of hypomagnesaemia and increased risk of fracture with long-term PPI use

23rd April 2012

The UK Medicines and Healthcare products Regulatory Agency (MHRA) have alerted healthcare professionals of the possible risks of hypomagnesaemia and also increased fracture risk with long-term Proton Pump Inhibitor (PPI) use (generally >1year) in their latest Drug Safety Update publication.


click here to view